New Phase 3 CASSINI Data Presented on the Use of XARELTO ® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news